NASDAQ:EPZM
Delisted
Epizyme Stock News
$1.47
+0 (+0%)
At Close: Nov 10, 2022
Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe
12:39pm, Thursday, 14'th Oct 2021
While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced th
Why Is Epizyme (EPZM) Up 3.8% Since Last Earnings Report?
01:16pm, Wednesday, 08'th Sep 2021
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
Epizyme's (EPZM) Q2 Earnings Miss, Revenues Beat Estimates
05:03pm, Tuesday, 10'th Aug 2021
Epizyme (EPZM) reports wider-than-expected loss for the second quarter of 2021 despite its revenues beating estimates. As a result, stock price declines.
Why Epizyme Is Getting Crushed Today
04:55pm, Monday, 09'th Aug 2021
It's uncomfortable when a company delivers an earnings miss and announces a CEO's departure on the same day.
Epizyme, Inc. (EPZM) CEO Rob Bazemore on Q2 2021 Results - Earnings Call Transcript
01:28pm, Monday, 09'th Aug 2021
Epizyme, Inc. (EPZM) CEO Rob Bazemore on Q2 2021 Results - Earnings Call Transcript
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates
10:04am, Monday, 09'th Aug 2021
Epizyme (EPZM) delivered earnings and revenue surprises of -5.00% and 48.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Epizyme Q2 Earnings
07:53am, Monday, 09'th Aug 2021
Shares of Epizyme (NASDAQ:EPZM) moved higher by 13.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 8.62% year over year to ($0.63), which
Epizyme Announces CEO Succession
07:35am, Monday, 09'th Aug 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies today announced its
Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update
07:30am, Monday, 09'th Aug 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today reported its secon
Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China
06:15am, Monday, 09'th Aug 2021
Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (tazemetostat) in Greater China, including ma
Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
08:00pm, Sunday, 08'th Aug 2021
CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Epizyme, Inc. (“Epizyme”) (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing a
Why Epizyme Stock Is Falling This Week
08:41am, Friday, 02'nd Jul 2021
The cancer drug developer's CFO will soon exit the company.
Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
02:28pm, Tuesday, 22'nd Jun 2021
Epizyme continues to advance its confirmatory studies to keep TAZVERIK on the market for treating patients with epithelioid sarcoma and follicular lymphoma.
Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models
12:59pm, Monday, 14'th Jun 2021
Epizyme Inc (NASDAQ: EPZM) has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2. The chromosomal abnormality is responsible for